Newborn Screening and Type 1 Diabetes: Historical Perspective and Current Activities at the CDC Division of Laboratory Sciences

Diabetes Technology and Therapeutics

Volumn 5, Issue 6, 2003, Pages 1017-1021

  Vogt Jr , Robert F ^a   Meredith, Nancy ^a   Henderson, L Omar ^a   Hannon, W Harry ^a,b  

^a NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH CARE QUALITY; HEALTH PROGRAM; HISTORY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY; MASS SCREENING; NEWBORN; NEWBORN SCREENING; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; UNITED STATES;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); DIABETES MELLITUS, TYPE 1; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; REPRODUCIBILITY OF RESULTS; UNITED STATES;

EID: 0346363773     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091503322641079     Document Type: Review

References (39)

1. Eisenbarth GS: Type 1 diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986;314:1360-1368.
2. Nerup J, Platz P, Andersen OO: HL-A antigens and diabetes mellitus. Lancet 1974;2:864-866.
3. Rewers M, Norris JM, Eisenbarth GS, Erlich HA, Beaty B, Klingensmith G, Hoffman M, Yu L, Bugawan TL, Blair A, Hamman RF, Groshek M, McDuffie RS Jr: Beta-cell autoantibodies in infants and toddlers without IDDM relatives: Diabetes Autoimmunity Study in the Young (DAISY). J Autoimmun 1996;9:405-410.
4. Simell O: Six years of type 1 diabetes prediction and prevention project in Finland. In: Proceedings of the 2001 Newborn Screening and Genetic Testing Symposium. Washington, DC: Association of Public Health Laboratories, 2001:40-48.
5. Ilonen J, Sjoroos M, Knip M, Veijola R, Simell O, Akerblom HK, Paschou P, Bozas E, Havarani B, Malamitsi-Puchner A, Thymelli J, Vazeou A, Bartsocas CS: Estimation of genetic risk for type 1 diabetes. Am J Med Genet 2002;115:30-36.
6. Berzina L, Shtauvere-Brameus A, Ludvigsson J, Sanjeevi CB: Newborn screening for high-risk human leukocyte antigen markers associated with insulin-dependent diabetes mellitus: the ABIS study. Ann N Y Acad Sci 2002;958:312-316.
7. Cinek O, Wilkinson E, Paltiel L, Saugstad OD, Magnus P, Ronningen KS: Screening for the IDDM high-risk genotype. A rapid microtitre plate method using serum as source of DNA. Tissue Antigens 2000;56:344-349.
8. Greener M: PANDA identifies babies at risk of developing type 1 diabetes. Mol Med Today 2001;6:3.
9. Hagopian W: Diabetes evaluation in Washington State. In: Proceedings of the 2001 Newborn Screening and Genetic Testing Symposium. Washington, DC: Association of Public Health Laboratories, 2001:49-50.
10. Glass M: Accessing residual dried blood spot specimens for a large scale population-based study to identify children with increased risk for type 1 diabetes. In: Proceedings of the 2002 Newborn Screening and Genetic Testing Symposium. Washington, DC: Association of Public Health Laboratories, 2002:106-114.
11. Sadeharju K, Hamalainen AM, Knip M, Lonnrot M, Koskela P, Virtanen SM, Ilonen J, Akerblom HK, Hyoty H, the Finnish TRIGR Study Group: Enterovirus infections as a risk factor for type I diabetes: virus analyses in a dietary intervention trial. Clin Exp Immunol 2003;132:271-277.
12. Bickel H, Gerrard J, Hickmans EM: The influence of phenylalanine intake on the chemistry and behavior of a phenylketonuric child. Acta Paediatr 1954;43:64-67.
13. Guthrie R, Susi A: A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-343.
14. Guthrie R: The origin of newborn screening. Screening 1992;1:5-15.
15. Dussault JH, Laberge C: Thyroxine (T4) determination in dried blood by radioimmunoassay: a screening test for neonatal hypothyroidism. Union Med Can 1973;102:2062-2064.
16. Mitchell ML, Larsen PR, Levy HL, Bennett AJ, Madoff MA: Screening for congenital hypothyroidism. Results in the newborn population of New England. JAMA 1978;239:2348-2351.
17. Hannon WH, Henderson LO, Bell CJ: Newborn screening quality assurance. In: Khoury M, Burke W, Thomson E, eds. Genetics and Public Health: Translating Advances in Human Genetics into Public Health Action. Oxford: Oxford University Press, 2000:243-258.
18. National Academy of Sciences: Genetic Screening: Programs, Principles, and Research. Washington, DC: National Academy Press, 1975:91.
19. Webster D, Dhondt JL, Hannon WH, Loeber G, Torresani T: Quality assurance and standardization: summary of the satellite meeting, Turku, Finland, 11-12 June 1999. Acta Paediatr Suppl 1999;88:7-12.
20. NCCLS: Blood Collection on Filter Paper for Neonatal Screening Programs, 4th ed. Approved Standard. NCCLS document LA4-A4. Wayne, PA: NCCLS, 2003.
21. Gwinn M, Redus MA, Granade TC, Hannon WH, George JR: HIV-1 serologic test results for one million newborn dried-blood specimens: assay performance and implications for screening. J Acquir Immune Defic Syndr 1992;5:505-512.
22. Swamy AR, Earley MC, Mei JV, Hannon WH: Multiplexed fluorescent bead immunoassay of human cytokines from dried blood spots. In: Proceedings of the 2002 Newborn Screening and Genetic Testing Symposium. Washington, DC: Association of Public Health Laboratories, 2002:387-392.
23. NCCLS: Assessing the Quality of Immunoassay Systems: Radioimmunoassays, and Enzyme, Fluorescence, and Luminescence Immunoassays. NCCLS document I/LA23. Wayne, PA: NCCLS, 2003.
24. NCCLS: Fluorescence Calibration and Quantitative Measurements of Fluorescence Intensity. NCCLS document I/LA24. Wayne, PA: NCCLS, 2003.
25. Proceedings from three international conferences on quantitative fluorescence cytometry (QFCM). Cytometry 1998;33:93-96.
26. Earley MA, Vogt RF, Shapiro HM, Mandy FF, Kellar KL, Bellisario R, Pass KA, Marti GE, Stewart CC, Hannon WH: Report from a workshop on multianalyte microsphere assays. Cytometry 2002;50:239-242.
27. Proceedings of a conference on a National Model for Standardization of Neonatal Hypothyroid Screening Programs. Atlanta, GA: Centers for Disease Control, U.S. Public Health Service, 1980.
28. Therrell BL Jr, Hannon WH, Pass KA, Lorey F, Brokopp C, Eckman J, Glass M, Heidenreich R, Kinney S, Kling S, Landenburger G, Meaney FJ, McCabe ER, Panny S, Schwartz M, Shapira E: Guidelines for the retention, storage, and use of residual dried blood spot samples after newborn screening analysis: statement of the Council of Regional Networks for Genetic Services. Biochem Mol Med 1996;57:116-124.
29. Centers for Disease Control and Prevention (CDC): Using tandem mass spectrometry for metabolic disease screening among newborns. MMWR Morbid Mortal Wkly Rep 2001;50(RR-03):1-34.
30. Centers for Disease Control and Prevention (CDC): Newborn screening for cystic fibrosis: a paradigm for public health genetics policy development. Proceedings of a 1997 workshop. MMWR Morbid Mortal Wkly Rep 1997; 46(RR-16):13-14.
31. Kalman L, Lindegren ML, Vogt R, Buckely R, Hannon WH, Spira T, Grosse S: Severe combined immunodeficiency disorder (SCID): a case for newborn screening? In: Proceedings of the 2002 Newborn Screening and Genetic Testing Symposium. Washington, DC: Association of Public Health Laboratories, 2002:313-316.
32. Kalman L: Newborn screening quality assurance program - proposed study: descriptive epidemiology of missed cases. In: Proceedings of the 2002 Newborn Screening and Genetic Testing Symposium. Washington, DC: Association of Public Health Laboratories, 2002:387-392.
33. Ford C: Multiple training modalities in newborn screening. In: Proceedings of the 2002 Newborn Screening and Genetic Testing Symposium. Washington, DC: Association of Public Health Laboratories, 2002:285-287.
34. Wasserfall C, Atkinson M, Jodoin E, Schatz D, She JX, Henderson LO, Ellis T: Glutamic acid decarboxylase and IA-2 autoantibodies in type 1 diabetes: comparing sample substrates for autoantibody determinations. Pediatr Diabetes 2000;1:10-16.
35. Henderson LO, Atkinson M, Bingley P, DBSTAR: Dried blood-spots as a matrix for type-1 diabetes autoantibody detection [abstract]. Diabetes 2001;49 (Suppl):A36.
36. Vogt RF: Newborn screening for type 1 diabetes: what to expect. In: Proceedings of the 2002 Newborn Screening and Genetic Testing Symposium. Washington, DC: Association of Public Health Laboratories, 2002:63-67.
37. Vogt RF, Schatz D: Benefits of type 1 diabetes screening. Adv Med Lab Prof 2003;15:13.
38. Bingley PJ, Bonifacio E, Ziegler AG, Schatz DA, Atkinson MA, Eisenbarth GS: Proposed guidelines on screening for risk of type 1 diabetes. Diabetes Care 2001;24:398.
39. Ross LF: Minimizing risks: the ethics of predictive diabetes mellitus screening research in newborns. Arch Pediatr Adolesc Med. 2003;157:89-95.